Real-World Injection Frequency and Cost of Ranibizumab and Aflibercept for the Treatment of Neovascular Age-Related Macular Degeneration and Diabetic Macular Edema

BACKGROUND: Ranibizumab and aflibercept are FDA-approved treatments for patients with neovascular age-related macular degeneration (nAMD) and diabetic macular edema (DME). Although these agents differ in cost and labeled dosing, it is unclear whether these differences are reflected in clinical pract...

Descripción completa

Detalles Bibliográficos
Autores principales: Kiss, Szilárd, Malangone-Monaco, Elisabetta, Wilson, Kathleen, Varker, Helen, Stetsovsky, Diana, Smith, David, Garmo, Vincent
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Academy of Managed Care Pharmacy 2020
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10390935/
https://www.ncbi.nlm.nih.gov/pubmed/32020843
http://dx.doi.org/10.18553/jmcp.2020.19245

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10390935/
https://www.ncbi.nlm.nih.gov/pubmed/32020843
http://dx.doi.org/10.18553/jmcp.2020.19245

Ejemplares similares